Gastroesophageal Cancer
The effects of primary tumor and LN volume on clinical outcomes in ESCC following neoadjuvant CCRT and surgery are unknown.
Dr. Rodón Ahnert compares the differences of sacituzumab tirumotecan use in the second- vs third-line setting for patients.
Pembrolizumab Shows Promise as a First-line Treatment for Advanced Gastric, Gastroesophageal Cancers
The final results from the KEYNOTE-811 trial will determine if Keytruda will receive continued approval from the FDA.
HERCESSI was developed by Accord BioPharma, Inc., the US specialty division of Intas Pharmaceuticals Ltd.
Dr. Ronan Kelly describes his trial on nivolumab with relatlimab for the treatment of resectable esophageal/GEJ cancer.
The prognostic value of the Edmonton Symptom Assessment Scale in patients with gastroesophageal cancer was investigated.
For those with a PD-L1 CPS of 5 or higher who received the combination therapy, the median OS was not achieved.
Chromoendoscopic screening can help reduce esophageal cancer incidence and mortality rates.
The trial’s primary endpoint was safety and the secondary endpoint was feasibility.
Tislelizumab correlated with a higher objective response rate and a better durable antitumor response versus chemotherapy.
Advertisement
Expert Interviews on GI Oncology
Advertisement
